-+ 0.00%
-+ 0.00%
-+ 0.00%
CMB International released a research report saying that the MSCI China Healthcare Index has accumulated a cumulative increase of 14.8% since the beginning of the year, outperforming the MSCI China Index by 32%. As the scale of BD transactions for innovative drugs overseas grows rapidly, the value of innovative pharmaceuticals going overseas depends on future milestone payments and sales shares. As the value of authorized varieties is realized, the valuations of related companies have a lot of room to rise. We recommend targets such as Yao Ming Biotech and Yingen Bio-B.
Share
Listen to the news
CMB International released a research report saying that the MSCI China Healthcare Index has accumulated a cumulative increase of 14.8% since the beginning of the year, outperforming the MSCI China Index by 32%. As the scale of BD transactions for innovative drugs overseas grows rapidly, the value of innovative pharmaceuticals going overseas depends on future milestone payments and sales shares. As the value of authorized varieties is realized, the valuations of related companies have a lot of room to rise. We recommend targets such as Yao Ming Biotech and Yingen Bio-B.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending